Stock ILMN ILLUMINA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Illumina, Inc.

Equities

ILMN

US4523271090

Real-time Estimate Cboe BZX
Other stock markets
 03:28:10 2024-04-30 pm EDT 		5-day change 1st Jan Change
123.3 USD -1.13% Intraday chart for Illumina, Inc. -0.93% -11.44%
Apr. 22 Bernstein Adjusts Price Target on Illumina to $129 From $150 MT
Apr. 22 Baird Adjusts Price Target on Illumina to $125 From $146, Neutral Rating Kept MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Illumina : 2024 Assurance Statement
PU
Illumina's planned divestment of GRAIL approved by the European Commission
AQ
Illumina's planned divestment of GRAIL approved by the European Commission
PR
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
PR
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
PR
GRAIL Presents New Data on Galleri and Its Methylation Platform at the Annual American Association for Cancer Research Meeting
AQ
Devyser Diagnostics AB publishes year-end report for January to December 2023
AQ
Illumina: Q4 Earnings Snapshot
AQ
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
PR
Curative Insurance Company Adds GRAIL's Galleri Test to Member Benefits for Multi-Cancer Early Detection
AQ
Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world
PR
BeniComp to Offer GRAIL's Multi-Cancer Early Detection Test for Employee Health Screening
AQ
Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
PR
Levi & Korsinsky Notifies Illumina, Inc.(ILMN) Investors of a Class Action Lawsuit and Upcoming Deadline
PR
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Illumina, Inc. (ILMN)
BU
Devyser signs in vitro diagnostic agreement with Illumina to broaden access to its tests
AQ
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Illumina, Inc. of Class Action Lawsuit and Upcoming Deadline - ILMN
PR
ILMN DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action - ILMN
NE
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
PR
The Gross Law Firm Notifies Shareholders of Illumina, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2024 - (NASDAQ: ILMN)
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ILMN Stock
  4. News Illumina, Inc.
  5. Press Releases